Find a Doctor
Dr. Chern is a Gynecologic Oncologist. After earning her Master’s Degree in Biochemistry and Molecular Biology at the Johns Hopkins University Bloomberg School of Public Health in Baltimore, Dr. Chern completed her Medical Degree at the University of South Florida College of Medicine. She subsequently completed her Residency in Obstetrics and Gynecology at the University of South Florida, where she served as Administrative Chief Resident and Scientific Review Committee Member. Dr. Chern completed her Gynecologic Oncology Fellowship at New York University School of Medicine, where she earned a Certificate in Translational Research Methodologies under the Clinical and Translational Science Institute. Her clinical focus is to provide personalized and comprehensive care for women with gynecologic cancers, with a special interest in the surgical management of advanced malignancies. Dr. Chern also emphasizes the utilization of minimally invasive surgery, including the Robotic platform. Dr. Chern’s research interest includes evaluating quality and safety measures to improve surgical outcomes in patients with malignancies. Dr. Chern has worked as part of a multi-disciplinary team to develop new protocols and safety measures with the goal of improving post-operative outcomes and patient satisfaction. In addition, her research is involved in understanding genetic factors associated with gynecologic malignancies to improve and guide patient care.
Education & Training
- New York University School of Medicine - Gynecologic Oncology
- Memorial Sloan Kettering - Galloway Fellowship
- University of South Florida - Obstetrics & Gynecology
- University of South Florida - MD
CLINICAL TRIAL 19641
A Randomized Phase 2 Study of Cabozantinib in Combination with Nivolumab in Advanced, Recurrent Metastatic Endometrial Cancer.
Intervention: BMS-936558 (Nivolumab); Cabozantinib (XL 184); Nivolumab; Not Applicable
CLINICAL TRIAL 16914
Sickness Behaviors in Gynecologic Cancer Patients Treated with Chemotherapy
CLINICAL TRIAL 18682
Determinants of Age-Related Treatment Effectiveness in Ovarian Cancer: Prospective Study of Pharmacokinetics Patterns and Underlying Biology.
Intervention: Paraplatin (carboplatin); Taxol (paclitaxel); carboplatin; paclitaxel
CLINICAL TRIAL 19112
DART: Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors
Intervention: BMS-936558 (Nivolumab); Ipilimumab; Nivolumab; Yervoy (Ipilimumab)
CLINICAL TRIAL 18983
A Randomized Multicenter Phase II Trial To Evaluate The Safety, Efficacy And Immunogenicity Of Vaccination With Folate Receptor Alpha Peptides Admixed With GM-CSF As A Vaccine Adjuvant Versus GM-CSF Alone In Patients With Platinum Sensitive Ovarian Cancer And A Response Or Stable Disease To Platinum Therapy
Intervention: FR alpha peptide vaccine; GM-CSF; Leukine (GM-CSF); sargramostatin (GM-CSF)
CLINICAL TRIAL 19421
A Phase 3, Randomized, Single Dose, Open-Label Study to Investigate the Safety and Efficacy of OTL38 Injection (OTL38) for Intra-operative Imaging of Folate Receptor Positive Ovarian Cancer
CLINICAL TRIAL 19399
A Phase 1b Study of Navicixizumab (OMP-305B83) plus Weekly Paclitaxel in Subjects with Platinum Resistant Ovarian, Primary Peritoneal or Fallopian Tube Cancer
Intervention: Navicixizumab; OMP-305B83 (Navicixizumab); Taxol (paclitaxel); paclitaxel
CLINICAL TRIAL 19479
A Phase 1-2 Study of the Combination of Olaparib and Tremelimumab in BRCA1 and BRCA2 Mutation Carriers with Recurrent Ovarian Cancer
Intervention: CP-675,206 (tremelimumab); Olaparib (Lynparza); tremelimumab
If you believe you are eligible for one of these trials or studies, please call
- Chern JY, Boyd LR, Blank SV. Uterine Sarcomas: The Latest Approaches for These Rare but Potentially Deadly Tumors. Oncology (Williston Park). 2017 Mar;31(3):229-236. Pubmedid: 28299760.
- Frey MK, Ellis AE, Koontz LM, Shyne S, Klingenberg B, Fields JC, Chern JY, Blank SV. Ovarian cancer survivors' acceptance of treatment side effects evolves as goals of care change over the cancer continuum. Gynecol Oncol. 2017 Aug;146(2):386-391. Pubmedid: 28602549.
- Lee J, Aphinyanaphongs Y, Curtin JP, Chern JY, Frey MK, Boyd LR. The safety of same-day discharge after laparoscopic hysterectomy for endometrial cancer. Gynecol Oncol. 2016 Sep;142(3):508-513. Pubmedid: 27288543.
- Frey MK, Moss HA, Musa F, Rolnitzky L, David-West G, Chern JY, Boyd LR, Curtin JP. Preoperative experience for public hospital patients with gynecologic cancer: Do structural barriers widen the gap?. Cancer. 2016 Mar;122(6):859-867. Pubmedid: 26938270.
- Chern JY, Curtin JP. Appropriate Recommendations for Surgical Debulking in Stage IV Ovarian Cancer. CURR TREAT OPTION ON. 2016 Jan;17(1):1. Pubmedid: 26714493.
- Frey MK, Kim SH, Bassett RY, Martineau J, Dalton E, Chern JY, Blank SV. Rescreening for genetic mutations using multi-gene panel testing in patients who previously underwent non-informative genetic screening. Gynecol Oncol. 2015 Nov;139(2):211-215. Pubmedid: 26296696.
- McLoughlin J, Melis M, Siegel E, Dean E, Weber J, Chern J, Elliott M, Kelley S, Karl R. Are patients with esophageal cancer who become PET negative after neoadjuvant chemoradiation free of cancer?. J Am Coll Surg. 2008 May;206(5):879-886. Pubmedid: 18471715.
- Hohenstein KA, Pyle AD, Chern JY, Lock LF, Donovan PJ. Nucleofection mediates high-efficiency stable gene knockdown and transgene expression in human embryonic stem cells. Stem Cells. 2008 Jun;26(6):1436-1443. Pubmedid: 18323409. Pmcid: PMC3882114.
- Charron M, Chern JY, Wright WW. The cathepsin L first intron stimulates gene expression in rat sertoli cells. Biol Reprod. 2007 May;76(5):813-824. Pubmedid: 17229931.